PURPOSE: To optimize the combination of ionizing radiation and cellular immunotherapy using a preclinical autochthonous model of prostate cancer. METHODS AND MATERIALS: Transgenic mice expressing a model antigen under a prostate-specific promoter were treated using a platform that integrates cone-beam CT imaging with 3-dimensional conformal therapy. Using this technology we investigated the immunologic and therapeutic effects of combining ionizing radiation with granulocyte/macrophage colony-stimulating factor-secreting cellular immunotherapy for prostate cancer in mice bearing autochthonous prostate tumors. RESULTS: The combination of ionizing radiation and immunotherapy resulted in a significant decrease in pathologic tumor grade and gross tumor bulk that was not evident with either single-modality therapy. Furthermore, combinatorial therapy resulted in improved overall survival in a preventive metastasis model and in the setting of established micrometastases. Mechanistically, combined therapy resulted in an increase of the ratio of effector-to-regulatory T cells for both CD4 and CD8 tumor-infiltrating lymphocytes. CONCLUSIONS: Our preclinical model establishes a potential role for the use of combined radiation-immunotherapy in locally advanced prostate cancer, which warrants further exploration in a clinical setting.
PURPOSE: To optimize the combination of ionizing radiation and cellular immunotherapy using a preclinical autochthonous model of prostate cancer. METHODS AND MATERIALS: Transgenic mice expressing a model antigen under a prostate-specific promoter were treated using a platform that integrates cone-beam CT imaging with 3-dimensional conformal therapy. Using this technology we investigated the immunologic and therapeutic effects of combining ionizing radiation with granulocyte/macrophage colony-stimulating factor-secreting cellular immunotherapy for prostate cancer in mice bearing autochthonous prostate tumors. RESULTS: The combination of ionizing radiation and immunotherapy resulted in a significant decrease in pathologic tumor grade and gross tumor bulk that was not evident with either single-modality therapy. Furthermore, combinatorial therapy resulted in improved overall survival in a preventive metastasis model and in the setting of established micrometastases. Mechanistically, combined therapy resulted in an increase of the ratio of effector-to-regulatory T cells for both CD4 and CD8 tumor-infiltrating lymphocytes. CONCLUSIONS: Our preclinical model establishes a potential role for the use of combined radiation-immunotherapy in locally advanced prostate cancer, which warrants further exploration in a clinical setting.
Authors: Elizabeth W Newcomb; Sandra Demaria; Yevgeniy Lukyanov; Yongzhao Shao; Tona Schnee; Noriko Kawashima; Li Lan; J Keith Dewyngaert; David Zagzag; William H McBride; Silvia C Formenti Journal: Clin Cancer Res Date: 2006-08-01 Impact factor: 12.531
Authors: Michael A Postow; Margaret K Callahan; Christopher A Barker; Yoshiya Yamada; Jianda Yuan; Shigehisa Kitano; Zhenyu Mu; Teresa Rasalan; Matthew Adamow; Erika Ritter; Christine Sedrak; Achim A Jungbluth; Ramon Chua; Arvin S Yang; Ruth-Ann Roman; Samuel Rosner; Brenna Benson; James P Allison; Alexander M Lesokhin; Sacha Gnjatic; Jedd D Wolchok Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245
Authors: James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut Journal: Clin Cancer Res Date: 2005-05-01 Impact factor: 12.531
Authors: Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S Babb; James P Allison; Silvia C Formenti Journal: Clin Cancer Res Date: 2005-01-15 Impact factor: 12.531
Authors: N M Greenberg; F DeMayo; M J Finegold; D Medina; W D Tilley; J O Aspinall; G R Cunha; A A Donjacour; R J Matusik; J M Rosen Journal: Proc Natl Acad Sci U S A Date: 1995-04-11 Impact factor: 11.205
Authors: J R Gingrich; R J Barrios; R A Morton; B F Boyce; F J DeMayo; M J Finegold; R Angelopoulou; J M Rosen; N M Greenberg Journal: Cancer Res Date: 1996-09-15 Impact factor: 12.701
Authors: Andrew B Sharabi; Phuoc T Tran; Michael Lim; Charles G Drake; Theodore L Deweese Journal: Oncology (Williston Park) Date: 2015-05 Impact factor: 2.990
Authors: Andrew B Sharabi; Christopher J Nirschl; Christina M Kochel; Thomas R Nirschl; Brian J Francica; Esteban Velarde; Theodore L Deweese; Charles G Drake Journal: Cancer Immunol Res Date: 2014-12-19 Impact factor: 11.151
Authors: Aleksandar Obradovic; Alok Kumar Singh; Kara A Lombardo; James L Liu; Gregory Joice; Max Kates; William Bishai; David McConkey; Alcides Chaux; Marie-Lisa Eich; M Katayoon Rezaei; George J Netto; Charles G Drake; Phuoc Tran; Andres Matoso; Trinity J Bivalacqua Journal: J Pathol Date: 2021-12-10 Impact factor: 7.996
Authors: Grit S Herter-Sprie; Shohei Koyama; Houari Korideck; Josephine Hai; Jiehui Deng; Yvonne Y Li; Kevin A Buczkowski; Aaron K Grant; Soumya Ullas; Kevin Rhee; Jillian D Cavanaugh; Neermala Poudel Neupane; Camilla L Christensen; Jan M Herter; G Mike Makrigiorgos; F Stephen Hodi; Gordon J Freeman; Glenn Dranoff; Peter S Hammerman; Alec C Kimmelman; Kwok-Kin Wong Journal: JCI Insight Date: 2016-06-16